|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| The Pharmacogenomics Outlook |
|
|
|
|
€ 955,00 |
Editeur
: |
Business Insight |
Langue
: |
Anglais |
Date de publication : |
Août 2000 |
Taille du document : |
174 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
Functional Proteomics and Emerging Bio-IT market
pages | Novembre 2002 |
The proteomic technique is not only limited to the study of one or few cellular products but also allows for qualitative and a quantitative measurement of several hundreds of proteins produced during |
250,00 €
|
| |
| |
04-012: How Life Scientists Buy Products: Implications for Effective Channel Management
303 pages | Mars 2004 |
This report is designed to help suppliers understand how researchers place orders and what drives them to use one method over another |
880,00 €
|
| |
| |
NanoBioTechnology: Trends and Technological Developments
18 pages | Février 2003 |
Nanobiotechnology is being projected as a great scientific and technological opportunity for the Bio world.
It is widely recognized as one of the most beneficial areas of nanotechnology to industry |
450,00 €
|
| |
| |
Human Genome: Its future
20 pages | Avril 2003 |
Genetic testing interests the companies and the government alike.
Companies are racing to understand and tap the mass of information pouring out of the Human Genome Project.
It is raising hopes |
400,00 €
|
| |
| |
DNA Computing-Tool for High-Performance Simulation
20 pages | Juillet 2002 |
The disciple of "DNA Computing" involves in cross-disciplinary research process between molecular and cellular biology involves the computational process in developing formal models of biological phen |
350,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets
150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry.
Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics.
V |
953,48 €
|
| |
| |
The Biotechnology Industry in US & Europe
22 pages | Mai 2002 |
A new report by RocSearch, The Biotechnology Industry in US & Europe, gives an overview of the global biotechnology industry.
It emphasizes current and emerging technologies including monoclonal an |
500,00 €
|
| |
| |
Integrating Genomics: The Next Generation
124 pages | Février 1999 |
Genomics research : Understand the key technologies including target identification (genome mapping, random sequencing and two-hybrid assay), target validation/assay development and current appli |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| The Pharmacogenomics Outlook |
|
|
Pharmaceutical companies are coming under increasing pressure to increase the
quality of their products, and optimize and accelerate drug discovery and development.
By identifying differences between patients’ genetic makeup and the effect this
has on drug response, pharmacogenomics has the potential to reduce medical costs,
improve drug development and therapy and cause a shift from treatment to prevention.
It is not suprising then, “that many leading industry figures believe pharmacoeconomics
will revolutionize the face of pharmaceutical drug development and , consequently
, clinical practice”.
The Pharmacogenomics Outlook coincides with the completion of the map
of the genome and the development of new technologies developed following this
breakthrough.
Benefiting from a survey of over 50 executives in leading pharmaceutical and
pharmacogenomics companies, this report provides a unique insight into the current
state and future direction of the pharmacogenomics market over the next ten
years.
It looks at the key industry drivers, identifies important strategic possibilities
and potential for collaboration.
|
|
Chapter 1: Background
Chapter 2: Pharmacogenomics – a Solution
Chapter 3: Technologies and Advances
Chapter 4: Market Issues
|
|
|
PPLSEN
|
|
|
|
|
